Similar Papers

Paper Title
Journal
Date
Author
Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy.
Sangmin Choi ... Woo-Young Sim
The Journal of dermatology | VOL. 51
Sangmin Choi, et. al.Sangmin Choi ... Woo-Young Sim
06 Feb 2024
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
Claus G Roehrborn ... Eric T Wolford
Urology | VOL. 63
Claus G Roehrborn, et. al.Claus G Roehrborn ... Eric T Wolford
01 Apr 2004
A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia
Walter Gubelin Harcha ... Dushen Chetty
Journal of the American Academy of Dermatology | VOL. 70
Walter Gubelin Harcha, et. al.Walter Gubelin Harcha ... Dushen Chetty
09 Jan 2014
Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.
Jung‐Won Shin ... Chang‐Hun Huh
The Journal of dermatology | VOL. 46
Jung‐Won Shin, et. al.Jung‐Won Shin ... Chang‐Hun Huh
07 Dec 2018
View more papers

More From: Journal of the American Academy of Dermatology

Paper Title
Journal
Date
Author
Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis
Benjamin Ungar ... Emma Guttman-Yassky
Journal of the American Academy of Dermatology | VOL. -
Benjamin Ungar, et. al.Benjamin Ungar ... Emma Guttman-Yassky
01 Feb 2025
CME examination
-
Journal of the American Academy of Dermatology | VOL. 92
--
01 Feb 2025
Systemic Sclerosis
Galen T Foulke ... Matthew F Helm
Journal of the American Academy of Dermatology | VOL. -
Galen T Foulke, et. al.Galen T Foulke ... Matthew F Helm
01 Feb 2025
Editorial Board
-
Journal of the American Academy of Dermatology | VOL. 92
--
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.